Anyone hear of AMBS-Dev Alzenheimer blood test and MANF. Worth the look
Stock is heading north.
Over the past several months, we've been following the emerging story at Amarantus BioScience Holdings, Inc. (AMBS.OB). Much of our interest in the story is based upon LymPro, the company's Alzheimer's Disease Blood Test based on Lymphocyte Proliferation. However, on August 12, 2013, Amarantus announced preclinical data with its therapeutic candidate, MANF, for the treatment of Retinitis Pigmentosa (RP). The idea of utility for MANF in this indication is interesting because RP qualifies as a potential orphan disease.